Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 57 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
OPNIPHAR from Buggenhout, company number BE0892559653, closed financial year 2025 with a result of € 43,653 after tax. For that financial year OPNIPHAR recorded a gross margin of € 627,366 and equity of € 534,041. Compared with financial year 2024, the result moved from € -3,313 to € 43,653. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on March 31, 2026.
€ 534,041
▲ 9% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 43,653
▲ still € 3,313 loss in 2024
Profit after tax over the fiscal year.
€ 154,326
▲ 7% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 515,491.
People and assets in 2025
5.5
▼ 0.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 384,422
▲ 6% vs 2024
€ 69,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 6,133
▼ 9% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 776,198
▼ 10% vs 2024
€ 86,875 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.
€ 213,860
▼ 12% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 50,834
▼ 4% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 545,828 | € 494,791 | € 543,671 | € 627,366 | ▲ 15% |
| Profit after taxes | € 77,477 | € -27,333 | € -3,313 | € 43,653 | ▲ € 46,966 |
| Equity | € 521,035 | € 493,701 | € 490,388 | € 534,041 | ▲ 9% |
| Total debts | € 1,628,342 | € 1,543,216 | € 1,481,578 | € 1,363,913 | ▼ 8% |
| Cash | € 244,406 | € 158,407 | € 144,856 | € 154,326 | ▲ 7% |
| Land & buildings | € 956,436 | € 925,627 | € 892,547 | € 859,468 | ▼ 4% |
| Retained profit | € 502,485 | € 475,151 | € 471,838 | € 515,491 | ▲ 9% |
| Bank debt | € 1,032,539 | € 947,797 | € 862,353 | € 776,198 | ▼ 10% |
| Balance sheet total | € 2,149,376 | € 2,036,917 | € 1,971,966 | € 1,897,954 | ▼ 4% |
| Employees (FTE) | 5.2 | 5.2 | 5.6 | 5.5 | ▼ 0.1 |
Key figures of OPNIPHAR, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to OPNIPHAR?
What happened at OPNIPHAR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 43,653. Source: NBB ↗
- Janpharma BV became a director. NBB
- Rita Segers became a director. NBB
- Hugo Heyvaert became a director. NBB
- Bex Pharma BV became a director. NBB
- BVU Consulting BV became a director. NBB
- New establishment in Buggenhout. KBO
- New establishment in Kapelle-op-den-Bos. KBO
In short
From € 77,477 profit in 2022 to € 43,653 profit in 2025.
Paid € 41,534 in corporate taxes since 2022.
Best year ever: 2022, with € 77,477 profit.
On average € 114,100 of value added per employee in 2025.
A new publication or filing at OPNIPHAR? We notify you, reason included.
Follow OPNIPHARDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Bex Pharma, JANPHARMA, BVU CONSULTING comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
OPNIPHARBehind OPNIPHAR are Janpharma BV, Rita Segers, Hugo Heyvaert, Bex Pharma BV and BVU Consulting BV. The shares are held by Bex Pharma (45%), JANPHARMA (45%) and BVU CONSULTING (10%).
Directors
According to the 2025 annual accounts
Bestuurder · represented by Jan Heyvaert
since 2023
Rita Segers
Bestuurder
since 2023
Hugo Heyvaert
Bestuurder
since 2023
Bestuurder · represented by Liesbet Heyvaert
since 2023
Bestuurder · represented by Brett Van Uytvanck
since 2023
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Broekstraat 28
9255 Buggenhout
Paddegatstraat 59
1880 Kapelle-op-den-Bos
Active since 4 October 2007
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0892.559.653
- VAT number
- BE 0892.559.653
- Registered office
- Broekstraat 28, 9255 Buggenhout
- Names & denominations
- OPNIPHAR
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 4 October 2007
- Peppol
- Active · Active since 24 Nov 2023
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers